Incidence and severity of SARS-CoV-2 infection in lung transplant recipients in the Omicron era DOI Creative Commons
Neval Ete Wareham, Sebastian Rask Hamm,

Regitze Hertz Liebermann

et al.

JHLT Open, Journal Year: 2023, Volume and Issue: 1, P. 100004 - 100004

Published: Sept. 20, 2023

SARS-CoV-2 infection may cause serious illness in lung transplant recipients. We aimed to investigate incidence and severity of recipients the Omicron era. conducted a retrospective study investigating COVID-19 outcomes among between December 27, 2021 October 31st, 2022 Denmark. performed COX regression analysis potential risk factors with hospitalization as an endpoint. Among 236 included patients, 108 had first positive PCR during total 133 person-years follow-up, resulting rate 813 per 1000 (95% CI 670-977). The cumulative was 24.1% 26 – 32.1) admission intensive care unit 3.7% 0.1 6.3). 30-day mortality 0.9% 0 2.7). found that patients markedly higher, whereas lower omicron era compared earlier reports for delta On other hand, substantial proportion were hospitalized, suggesting continuous impact on this patient population.

Language: Английский

SARS-CoV-2 breakthrough infections enhance T cell response magnitude, breadth, and epitope repertoire DOI Creative Commons
Alison Tarke,

Parham Ramezani-Rad,

Tertuliano Alves Pereira Neto

et al.

Cell Reports Medicine, Journal Year: 2024, Volume and Issue: 5(6), P. 101583 - 101583

Published: May 22, 2024

Little is known about the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or SARS2) vaccine breakthrough infections (BTIs) on magnitude and breadth T cell repertoire after exposure to different variants. We studied samples from individuals who experienced symptomatic BTIs during Delta Omicron waves. In pre-BTI samples, 30% donors exhibited substantial immune memory against non-S (spike) SARS2 antigens, consistent with previous undiagnosed asymptomatic infections. Following BTI, we observed (1) enhanced S-specific CD4 CD8 responses in without infection, (2) expansion targets (M, N, nsps) independent variant, (3) generation novel epitopes recognizing variant-specific mutations. These accounted for 9%-15% total epitope repertoire. Overall, boost vaccine-induced by increasing broadening antigens recognized.

Language: Английский

Citations

4
JN.1 variants circulating in Italy from October 2023 to April 2024: genetic diversity and immune recognition DOI Creative Commons
Emanuela Giombini, Ilaria Schiavoni, Luigina Ambrosio

et al.

BMC Infectious Diseases, Journal Year: 2025, Volume and Issue: 25(1)

Published: Feb. 28, 2025

The continuous emergence of SARS-CoV-2 variants and subvariants poses significant public health challenges. latest designated subvariant JN.1, with all its descendants, shows more than 30 mutations in the spike gene. JN.1 has raised concerns due to genomic diversity potential enhance transmissibility immune evasion. This study aims analyse molecular characteristics JN.1-related lineages (JN.1*) identified Italy from October 2023 April 2024 evaluate neutralization activity against a subsample sera individuals vaccinated XBB.1.5 mRNA. gene 794 JN.1* strain was evaluated phylogenetic analysis conducted compare distance XBB.1.5. Moreover, serum assays were performed on 19 healthcare workers (HCWs) monovalent mRNA booster assess neutralizing capacity JN.1. Sequence displayed high variability between investigation confirmed substantial differentiation regions 29 shared mutations, which 17 located within RBD region. Pre-booster observed 42% HCWs sera, increasing significantly post-booster, showing three months after vaccination. A correlation found anti-trimeric Spike IgG levels titers highlights Italy. Results vaccine suggested enhanced

Language: Английский

Citations

0
Longitudinal Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Immunity Over 2 Years Following Vaccination and Infection DOI Creative Commons
Anna Karina Juhl, Lisa Loksø Dietz, Ole S. Søgaard

et al.

The Journal of Infectious Diseases, Journal Year: 2024, Volume and Issue: 230(3), P. e605 - e615

Published: April 30, 2024

Within a year of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, vaccines inducing robust humoral and cellular immune response were implemented worldwide. However, emergence novel variants waning vaccine-induced immunity led to implementation additional vaccine boosters.

Language: Английский

Citations

2
Blood T cell phenotypes correlate with fatigue severity in post-acute sequelae of COVID-19 DOI Creative Commons
Isabell Pink, Jan K. Hennigs, Louisa Ruhl

et al.

Infection, Journal Year: 2023, Volume and Issue: 52(2), P. 513 - 524

Published: Nov. 4, 2023

Abstract Purpose Post-acute sequelae of COVID-19 (PASC) affect approximately 10% convalescent patients. The spectrum symptoms is broad and heterogeneous with fatigue being the most often reported sequela. Easily accessible blood biomarkers to determine PASC severity are lacking. Thus, our study aimed correlate immune phenotypes across COVID-19. Methods A total 176 originally immunonaïve, patients from a prospective cohort during first pandemic phase were stratified by initial disease underwent clinical, psychosocial, phenotyping around 10 weeks after symptoms. COVID-19-associated dynamics assessed related clinical phenotypes. Results Fatigue severe commonly irrespective or organ-specific PASC. clinically relevant increase in was detected all groups. Neutralizing antibody titers higher acute disease, but no association found between While absolute peripheral cell counts immunonaïve did not differ unexposed controls, CD3 + CD4 T independently correlated strata multivariable analysis. Conclusions Patients at similar risk self-reported severity. independent correlation indicates possible role cells pathogenesis post-COVID-19 fatigue, which might serve as biomarker.

Language: Английский

Citations

3
The varying extent of humoral and cellular immune responses to either vector- or RNA-based SARS-CoV-2 vaccines persists for at least 18 months and is independent of infection DOI Creative Commons
Franz Mai,

Wendy Bergmann,

Emil C. Reisinger

et al.

Journal of Virology, Journal Year: 2024, Volume and Issue: 98(4)

Published: March 19, 2024

The corona virus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome corona-virus 2 (SARS-CoV-2) spurred a worldwide race for the development of an efficient vaccine. Various strategies were pursued; however, first vaccines to be licensed presented SARS-CoV-2 spike protein either in context non-replicating adenoviral vector or as mRNA construct. While short-term efficacies have extensively been characterized, duration protection, need repeated boosting, and reasonable vaccination intervals yet defined. We here describe adaptive immune response resulting from homologous heterologous regimen at 18 months after primary vaccination. To that extent, we monitored 176 healthcare workers, majority whom had recovered previous infection. In summary, find differences depending on immunization continue exist these findings hold true irrespective infection with virus. Homologous BNT162b2 was repeatedly shown produce higher antibody levels slower decline, leading more effective

Language: Английский

Citations

0
The Protective Efficacy of a SARS-CoV-2 Vaccine Candidate B.1.351V against Several Variant Challenges in K18-hACE2 Mice DOI Creative Commons
J.E. Yang,

Huifen Fan,

Anna Yang

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(7), P. 742 - 742

Published: July 3, 2024

The emergence of SARS-CoV-2 variants concern (VOCs) with increased transmissibility and partial resistance to neutralization by antibodies has been observed globally. There is an urgent need for effective vaccine combat these variants. Our study demonstrated that the B.1.351 variant inactivated candidate (B.1.351V) generated strong binding neutralizing antibody responses in BALB/c mice against virus other after two doses within 28 days. Immunized K18-hACE2 also exhibited elevated levels live virus-neutralizing various viruses. Following infection viruses, displayed a stable body weight, high survival rate, minimal copies lung tissue, no damage compared control group. These findings indicate B.1.351V offered protection multiple mice, providing insights development targeting VOCs human use.

Language: Английский

Citations

0
Comparable and sustained levels of S1-RBD-IgG and S1-RBD-IgA in BNT162b2 homologous and CoronaVac-BNT162b2 heterologous booster vaccination: A 22-month prospective study in Malaysia DOI

Anis Atifah Mohd Hisham,

Aini Syahida Mat Yassim, Rapeah Suppıan

et al.

Vaccine, Journal Year: 2024, Volume and Issue: 42(26), P. 126471 - 126471

Published: Oct. 28, 2024

Language: Английский

Citations

0
Clinical characteristics and antibody response to Omicron variants among solid carcinoma patients in China on the 2022.12–2023.4 wave of the COVID-19 pandemic DOI Creative Commons

Rongrong Dai,

Weiyu Peng,

Nani Xu

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 6, 2024

Background China experienced a surge of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants after adjusting its zero-coronavirus disease 2019 (COVID-19) policy. Although infections with are generally less than previous SARS-CoV-2 variants, the clinical characteristics, persistent symptoms, and antibody responses in solid carcinoma patients (SCPs) COVID-19 during wave unclear. Methods We conducted cross-sectional study April 2023, recruiting healthy controls (HCs) from community SCPs Zhejiang Provincial People’s Hospital. Serum samples were collected, questionnaire was used to assess infection status, including demographic manifestations, “long COVID” symptoms. Humoral immune analyzed by enzyme-linked immunosorbent assays (ELISAs) targeting immunoglobulin G (IgG) antibodies against receptor-binding domain (RBD; BA.4/5) protein cell culture-based neutralization (BA.4/5, BF.7, XBB.1.5, EG.5). Results In total, 298 258 HCs enrolled. Self-reported case rates significantly lower (78.5% vs. 93.8%, P<0.001). Common symptoms similar between two groups, primarily comprising general (92.6% 84.9%) (51.9% 48.2%) infection. There no significant difference at 1–3 months post-infection (P=0.353); fatigue most common symptom (45.0% 44.8%). exhibited anti-RBD-IgG titers compared (1.061 1.978, P=0.001). The 50% pseudovirus titer (pVNT 50 ) values for prevalent strains (BA.4/5 BF.7) (621.0 [288.8, 1333.0] 894.1 [458.5, 1637.0] 529.6 [215.3, 1264.5] 463.1 [185.2, 914.0], respectively). Levels subsequent (XBB.1.5 EG.5) also reduced. differences among types levels variants. However, who received vaccine or had displayed higher levels. Conclusions This elucidated immunological characteristics shift away zero-COVID-19 Our findings provide insights regarding factors that influence this population.

Language: Английский

Citations

0
Diminished Neutralization Capacity of SARS-CoV-2 Omicron BA.1 in Donor Plasma Collected from January to March 2021 DOI Creative Commons
Yi-Chan Lin, David H. Evans,

Ninette F Robbins

et al.

Microbiology Spectrum, Journal Year: 2023, Volume and Issue: 11(4)

Published: June 8, 2023

The 50% plaque reduction neutralization assay (PRNT

Language: Английский

Citations

1
A two-arm analysis of the immune response to heterologous boosting of inactivated SARS-CoV-2 vaccines DOI Creative Commons
Arnone Nithichanon,

Ludthawun Kamuthachad,

Kanin Salao

et al.

Scientific Reports, Journal Year: 2023, Volume and Issue: 13(1)

Published: Oct. 31, 2023

Several vaccine programs were introduced during the COVID-19 pandemic, which included inactivated virus, DNA viral vectors and mRNA vaccines. Booster are recommended, especially for those in high-risk groups. However, many of these booster involve heterologous This study enrolled volunteers who first received two full-dose CoronaVac vaccinations before receiving boosters with DNA- and/or mRNA-vaccines an additional 2 doses (n = 40) or 3 16). Our results showed no difference side effects, neutralizing antibodies, T-cell responses any vaccination programs. capacity IFN-γ against Omicron variant 4 5 improved. Polarization peripheral memory T cells after stimulation all groups peptide increased trend naïve central phenotypes both CD4+ CD8+ cells, suggesting that exposure to antigens will drive into a lymphoid resident cell phenotype. data support continuous program maximize effectiveness immunity, people at high risk. Furthermore, number boosting is important maintaining immunity.

Language: Английский

Citations

1